Pharmafile Logo
Pharmafocus logo
Advanced Search

HIV

Showing 15 posts of 200 posts found.

hiv-infected_h9_t-cell_-_credit_national_institutes_of_health-web

New research reverses HIV-related immune suppression

December 21, 2016
Research and Development HIV, UNC School of Medicine

The UNC School of Medicine has released new research which appears to offer a new approach to HIV treatment which …

News
janssen_stairs

Collaboration on new therapeutic vaccine for HIV shows promise

November 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Janssen, Johnson & Johnson

Janssen, part of Johnson & Johnson, released details on 9 November of the results of a new study looking into …

News
hiv-infected_h9_t-cell_-_credit_national_institutes_of_health-web

Kymab demonstrates promising research for HIV vaccine development

September 9, 2016
Medical Communications, Research and Development HIV, Vaccine, kymab

Cambridge-based antibodies-to-medicines company Kymab has announced publication of research testing the first step in the effort to develop effective vaccines …

News
gilead-sciences

Gilead gets EU approval for HIV-prevention treatment Truvada

August 23, 2016
Manufacturing and Production, Sales and Marketing EU, Gilead, HIV, PrEP, Truvada, prevention

Gilead Sciences has received marketing authorisation from the European Commission for once-daily Truvada (emtricitabine/tenofovir disoproxil), in combination with safer sex …

News
landing-hero-images1

ViiV Healthcare launches Phase III trial for combo HIV treatment

August 16, 2016
Research and Development Dolutegravir, HIV, Tivicay, ViiV Healthcare, epivir, lamivudine, phase III

The Pfizer/GSK spin off ViiV Healthcare has announced the beginning of a Phase III evaluating Tivicay (dolutegravir) and Epivir (lamivudine) …

News
gilead-sciences

Gilead to work with Genmab on HIV targeting technology

August 12, 2016
Medical Communications, Research and Development, Sales and Marketing Genmab, Gilead, HIV, duobody

Genmab has announced that it has entered into a collaboration deal with Gilead Sciences to use the DuoBody technology platform …

News
gilead-sciences

EU recommends PrEP in Gilead’s HIV prevention treatment

July 25, 2016
Research and Development, Sales and Marketing EU, Gilead, HIV, PrEP, prevention

Gilead has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines …

News
gilead-sciences

EU grants approval for Gilead’s HIV treatment Descovy

April 26, 2016
Manufacturing and Production, Research and Development EU, HIV, approval, descovy, taf

Gilead Sciences (NASDAQ: GILD) has announced that the fixed-dose combination HIV treatment, Descovy (emtricitabine, tenofovir alafenamide), has been granted marketing …

News
iqwigsmall

IQWiG says Gilead’s anti-HIV drug genvoya offers slightly lower benefits than competition

April 11, 2016
Medical Communications, Research and Development Bristol-Myers Squibb, Gilead, HIV, anti-HIV

German Institute for Quality and Efficiency in Health Care (IQWiG) said USdrug maker Gilead’s (Nasdaq: GILD) anti-HIV drug Genvoya provides marginally …

News
hiv-infected_h9_t-cell_-_credit_national_institutes_of_health-web

HIV successfully overcomes CRISPR gene-editing technology

April 8, 2016
Research and Development HIV, crispr, failure, setback

Researchers using the CRISPR gene-editing technology have indicated that HIV can defeat efforts to cripple it, but have characterised it …

News
descovy

FDA approves Gilead’s latest HIV treatment

April 5, 2016
Manufacturing and Production, Research and Development Gilead, HIV, descovy, taf, taf-based, therapy

Gilead (NASDAQ: GILD) has announced that the US Food and Drug Administration has approved their TAF-based HIV therapy, Descovy (emtricitabine, …

News
janssen_latest_logo_on_sign

Janssen-Cilag’s HIV treatment gets NHS backing

March 31, 2016
Manufacturing and Production, Research and Development, Sales and Marketing HIV, Janssen, NHS, drug trial

Janssen-Cilag Ltd (Janssen) has said NHS England (NHSE) will fund its combination treatment for HIV.  The company said following the …

News
fda_building

FDA bans clinical trial co-ordinator who faked patient samples and stole funds

March 22, 2016
Manufacturing and Production, Medical Communications FDA, HIV, clinical trials, faked, forgery, mcquerry, prison

The US Food and Drug Administration has permanently banned a clinical trial co-ordinator who was found to have falsified patient …

News
gilead-sciences

FDA approves Gilead’s Odefsey for treatment of HIV-1 infection

March 2, 2016
Research and Development, Sales and Marketing Gilead Sciences, HIV, Odefsey

Gilead Sciences has announced that the US Food and Drug Administration (FDA) has approved its TAF-based single tablet regimen Odefsey …

News
viiv_healthcare

ViiV completes BMS HIV pipeline purchase

February 23, 2016
Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, GSK, HIV, Pfizer, Shionogi, ViiV

ViiV Healthcare has completed its previously-announced acquisition of Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025